Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS–mutated non-small cell lung cancer (NSCLC): A result of nationwide genomic screening project (LC-SCRUM-Japan). This is ...
Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM). This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This ...
One of the hottest questions these days, whether online or in the boardroom, is “How does the organization become more ‘agile’?” As the discussion evolves, it leads to, “How do we scale agility from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results